7-Hydroxymitragynine Causes Morphine-Level Respiratory Depression Reversible by Naloxone, Rat Study Finds

Why it matters

This study provides the clearest preclinical evidence yet that 7-hydroxymitragynine — the concentrated alkaloid increasingly found in commercial kratom products — causes dangerous respiratory depression comparable to morphine, and that naloxone can reverse it. The finding has direct implications for overdose response and how regulators classify kratom-derived products.

The big picture

While kratom's primary alkaloid mitragynine is generally regarded as having a lower abuse liability, 7-hydroxymitragynine (7-HMG) is a semi-synthetic derivative increasingly marketed at concentrations up to 98% purity. FDA has already requested DEA scheduling of 7-HMG as a Schedule I substance. This study, supported by NIDA grant funding and conducted at the University of Florida College of Pharmacy and Texas Tech Health Sciences Center, used whole-body plethysmography in rats to directly measure breathing parameters following drug administration.

Key findings

• 7-HMG induced significant dose-dependent respiratory depression, including reductions in breathing frequency, tidal volume, and minute volume
• 7-HMG was 4.5 times more potent than morphine in causing respiratory depression by 50% of minute volume
• Naloxone fully reversed the respiratory depression caused by both morphine and 7-HMG, confirming opioid receptor involvement
• Mitragynine (the natural primary alkaloid in kratom) unexpectedly increased respiratory frequency — acting as a respiratory stimulant rather than a depressant
• Mitragynine's respiratory effects were not reversed by naloxone, indicating it acts through non-opioid pathways

What they say

These findings highlight critical pharmacological differences between kratom-related alkaloids, emphasizing potential risks associated with products containing high concentrations of 7-HMG, the authors wrote in the study's Significance Statement.

Bottom line

Kratom's most abundant natural alkaloid (mitragynine) appears respiratory-safe and non-opioid, while concentrated 7-HMG acts like a potent opioid — a critical distinction that supports treating these two substances differently under law.